NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Wednesday, September 4, 2024 at 10:00 a.m. ET in New York, NY
Baird’s 2024 Global Healthcare Conference
Wednesday, September 11, 2024 at 11:25 a.m. ET in New York, NY
2024 Cantor Global Healthcare Conference
Wednesday, September 18, 2024 at 10:55 a.m. ET in New York, NY
A live and achieved webcast of the presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
646-930-4406


Đề xuất
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY